8-K: Carlsmed Reports Strong Q2 Growth, Raises Full-Year Guidance

Carlsmed, Inc. announced robust second quarter 2026 financial results, showcasing 57% year-over-year revenue growth and an increase in gross margins, leading to an upward revision of its full-year revenue outlook.

Summary

• Carlsmed reported second quarter 2026 revenue of $18.9 million, a 57% increase compared to $12.1 million in the same period last year.
• Gross profit rose to $14.5 million from $8.9 million year-over-year, with gross margin improving to 76.8% from 73.4%.
• Operating expenses increased to $25.6 million from $15.4 million, driven by higher R&D, sales & marketing, and G&A costs.
• The company reported a net loss of $10.5 million for the quarter, compared to a $6.8 million net loss in Q2 2025.
• Adjusted EBITDA was a loss of $8.6 million, an increase from a loss of $6.2 million in the prior year's quarter.
• Full-year 2026 revenue guidance has been raised to a range of $74 million to $78 million, representing over 50% growth at the midpoint.
• Cash and cash equivalents, restricted cash, and investments totaled $89.3 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved gross margins, and raised full-year guidance, despite continued net losses.

Positives

• Revenue grew by 57% year-over-year to $18.9 million in Q2 2026.
• Gross margin expanded by 340 basis points to 76.8% in Q2 2026.
• Trained surgeon user base increased by over 60% year-over-year.
• Full-year 2026 revenue guidance was raised to $74-$78 million.
• The aprevo cervical procedure, in its second full quarter of commercialization, now represents approximately 10% of quarterly revenue.
• A favorable CMS ruling for aprevo lumbar procedures, effective October 1, 2026, is expected to enhance hospital reimbursement.

Negatives

• Net loss widened to $10.5 million in Q2 2026 from $6.8 million in Q2 2025.
• Adjusted EBITDA loss increased to $8.6 million in Q2 2026 from $6.2 million in Q2 2025.
• Operating expenses significantly increased by $10.2 million year-over-year, primarily in sales & marketing and G&A.

Risks

• Actual results may differ materially from forward-looking statements due to various important factors, including those set forth in the company's Form 10-K.
• The company is still operating at a net loss, indicating ongoing profitability challenges.

Future Outlook

Full-year 2026 revenue is projected to be between $74 million and $78 million, an increase from prior guidance and representing over 50% growth at the midpoint compared to 2025. The company anticipates continued growth driven by strong volume trends and a robust pipeline, further bolstered by the upcoming CMS ruling on reimbursement for aprevo lumbar procedures.

Management Comments

• "Our second quarter 2026 results reflect the growing momentum of aprevo procedures and further progress on our path to profitability," said Mike Cordonnier, Chairman and Chief Executive Officer.
• "We delivered 57% revenue growth year-over-year, expanded gross margins by 340 basis points, and grew our trained surgeon user base by more than 60% over the prior year."
• "We continue to see strong volume growth across lumbar and cervical aprevo procedures, with continued advancements in our proprietary digital production system enabling scalability ahead of strong market demand."
• "We believe the recent CMS ruling which takes effect on October 1, 2026, and provides new and enhanced hospital reimbursement for the aprevo lumbar procedure positions us well for ongoing growth in the years to come."

Industry Context

StockSavvy.ai notes that Carlsmed's focus on AI-enabled personalized spine surgery solutions aligns with the broader trend in medtech towards data-driven, patient-specific treatments. The company's ability to scale production and secure favorable reimbursement, as indicated by the CMS ruling, are critical factors for success in this competitive and highly regulated market.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and raised guidance, but continued net losses may be a concern.
• Patients: Potential for improved surgical outcomes and access to innovative treatments through aprevo procedures.
• Hospitals/Surgeons: Increased reimbursement for aprevo lumbar procedures is a positive development, potentially driving adoption.
• Creditors: Company maintains a healthy cash balance ($89.3 million), suggesting ability to meet short-term obligations.

Next Steps

• Continue to grow surgeon adoption and user base.
• Leverage the upcoming CMS ruling for increased aprevo lumbar procedure access and reimbursement.
• Scale proprietary digital production system to meet market demand.
• Focus on path to profitability.

Key Dates

Recommendation

The company demonstrates strong top-line growth and positive strategic developments like the CMS ruling, which are encouraging. However, the widening net loss and increased operating expenses, coupled with the ongoing need for significant investment, suggest that while the company is executing well operationally, profitability remains a longer-term goal. This warrants a 'hold' rating until a clearer path to profitability emerges or sustained positive earnings are demonstrated.

Keywords

spine surgery, medical technology, AI-enabled, personalized surgery, revenue growth, CMS ruling, reimbursement, financial results